Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice $(GLP)$ toxicology studies. These efforts are aimed at supporting an Investigational New Drug $(IND.AU)$ application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.